Literature DB >> 16305646

Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.

V Peruhype-Magalhães1, O A Martins-Filho, A Prata, L de A Silva, A Rabello, A Teixeira-Carvalho, R M Figueiredo, S F Guimarães-Carvalho, T C A Ferrari, R Correa-Oliveira.   

Abstract

We investigated the cytokine profile of cells of the innate immune response and its association with active (ACT), asymptomatic (AS) and cured (CUR) human visceral leishmaniasis (VL), as well as noninfected (NI) subjects. The frequency of cytokine-producing cells was determined after short-term in vitro incubation of whole peripheral blood samples with soluble Leishmania antigen (SLA). Our data demonstrated a predominant type 2 cytokine profile in NI and ACT. In NI, we observed an increase of IL-4+ neutrophils, IL-10+ eosinophils besides a decrease of tumour necrosis factor (TNF)-alpha+ eosinophils/monocytes. Yet in ACT, we observed an increase of IL-4+ neutrophils and natural killer (NK) cells and IL-10+ monocytes, a reduced frequency of IL-12+ and IFN-gamma+ eosinophils and lower levels of TNF-alpha+ and IL-12+ monocytes. AS presented a mixed profile, characterized by an increase of IFN-gamma+ neutrophils/eosinophils and NK cells, of IL-12+ eosinophils/monocytes, as well as increase of IL-4+ neutrophils and NK cells and IL-10+ eosinophils/monocytes. In contrast, CUR was characterized by a type 1 response with an increase of IFN-gamma+ neutrophils/eosinophils and NK cells, associated with an increase in IL-12+ monocytes. In conclusion, we show a correlation between innate immune cytokine patterns and clinical status of VL, suggesting that these cells, in addition to other factors, may contribute to the cytokine microenvironment in which Leishmania-specific T cells are primed and to disease outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305646     DOI: 10.1111/j.1365-3083.2005.01686.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

1.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

2.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

3.  Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.

Authors:  Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

4.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

5.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

6.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

7.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

Review 8.  Eosinophils and mast cells in leishmaniasis.

Authors:  Nilda E Rodríguez; Mary E Wilson
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

9.  Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis.

Authors:  Prashant Khare; Anil Kumar Jaiswal; Chandra Dev Pati Tripathi; Sumit Joshi; Shyam Sundar; Anuradha Dube
Journal:  Parasitol Res       Date:  2013-12-27       Impact factor: 2.289

10.  Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.

Authors:  Pramod K Kushawaha; Reema Gupta; Chandra Dev Pati Tripathi; Prashant Khare; Anil Kumar Jaiswal; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.